Literature DB >> 10081101

[Lymph node staging of bladder neck carcinoma with positron emission tomography].

R Bachor1, J Kotzerke, S N Reske, R Hautmann.   

Abstract

PET is a new method in nuclear medicine which examines the metabolism and not the morphology. Tumors show a higher rate of glycolysis than benign tissue and hence can be detected by radioactive glucose. This method has proved good for various tumors. In this study the lymph node staging of bladder cancer by PET was investigated. In 64 patients a PET of the pelvis after injection of fluorodeoxyglucose (FDG) was carried out preoperatively; the PET-results were compared with the histology of the OR specimen after classical pelvic lymphadenectomy. For lymph node staging positive nodes were found in 14 patients which was correct; a false-negative result was obtained in 7 patients. In 37 patients the PET-result was true-negative and in 6 patients false-positive resulting in a sensitivity of 67%, a specificity of 86% and an accuracy of 80%. Therefore, our PET results are encouraging and seem to be better than those obtained by classical staging procedures such as CT or MRI.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081101     DOI: 10.1007/s001200050244

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  13 in total

Review 1.  New imaging modalities in bladder cancer.

Authors:  Mansi A Saksena; Douglas M Dahl; Mukesh G Harisinghani
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

Authors:  Andrea B Apolo; Jamie Riches; Heiko Schöder; Oguz Akin; Alisa Trout; Matthew I Milowsky; Dean F Bajorin
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

3.  FDG-PET for preoperative staging of bladder cancer.

Authors:  O Drieskens; R Oyen; H Van Poppel; Y Vankan; P Flamen; L Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-31       Impact factor: 9.236

Review 4.  [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers].

Authors:  J Stattaus; A Bockisch; M Forsting; S P Müller
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

Review 5.  [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].

Authors:  S Machtens; A R Boerner; M Hofmann; W H Knapp; U Jonas
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

Review 6.  PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  PET Clin       Date:  2015-04-24

7.  PET/CT and MRI in Bladder Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  J Cancer Sci Ther       Date:  2012-07-30

Review 8.  Current role of PET, CT, MR for invasive bladder cancer.

Authors:  Nathan Lawrentschuk; Sze Ting Lee; Andrew M Scott
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

Review 9.  Positron emission tomography (PET) in the urooncological evaluation of the small pelvis.

Authors:  S Machtens; J Serth; A Meyer; C Kleinhorst; K-J Ommer; U Herbst; M Kieruij; A R Boerner
Journal:  World J Urol       Date:  2007-07-12       Impact factor: 4.226

10.  [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma.

Authors:  Hossein Jadvar; Vicki Quan; Robert W Henderson; Peter S Conti
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.